NCT07665060进行中（未招募）不适用
Assessing HIV Antibody Increases Following Viral Rebound in People Receiving Antiretroviral Therapy
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 6,100
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to establish a proof-of-concept for whether rapid test can detect viral rebounds that occurred within a retrospective time window among PLHIV receiving ART in the United States and sub-Saharan Africa.
The objective of this study is to assess whether HIV antibody levels rise following HIV viral rebound, and the sensitivity and specificity of antibody level increases for detecting HIV viral rebounds.
The investigators will conduct a retrospective matched case-control study of individuals with or without suppressed viral load on antiretroviral therapy (ART). Biobanked specimens will be tested for antibody levels.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 15 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HIV-positive individuals aged 15 or older at the time of ART initiation.
- •Participated in HIV plasma or serum biobanking and viral load testing, with three samples after January 1, 2015 as follows:
- •T1 specimen with suppressed VL and sufficient sample to conduct antibody testing.
- •T2 specimen collected 1-13 months after T1, with: Cases: unsuppressed VL; Controls: suppressed VL.
- •T3 specimen collected 1-13 months after T2, with sufficient sample to conduct antibody testing.
- •At least one VL measurement recorded prior to T1, with:
- •All VL measurements made in the year prior to T1 showing suppressed VL.
- •If no VL measurements were made in the year prior to T1, the most recent VL measurement made prior to T1 showing suppressed VL.
排除标准
- •Individuals with advanced HIV disease from 1 year prior to T1 until T3, defined as:
- •CD4 cell count <200 cells/mm
- •Any AIDS-defining illnesses.
- •Individuals with severe illness or hospitalization from 1 year prior to T1 until T
- •Individuals with immune disorder or cancer diagnosis from 1 year prior to T1 until T
- •Individuals with known recent infection at time of ART initiation (ART initiated within 1 year of estimated date of detectable infection).
- •Individuals known to have been infected with HIV perinatally.
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1HIVNCT07390955National Institute of Allergy and Infectious Diseases (NIAID)83
Unknown
不适用
HIV 感染者接种新冠(COVID-19)灭活疫苗加强针的安全性、免疫原性的前瞻性队列研究ChiCTR2200058989北京科兴中维生物技术有限公司500
Unknown
不适用
成人早期 HIV 感染者抗病毒治疗临床研究方案ChiCTR-ONRC-13003483“十二五”重大科技专项课题 (2012ZX10001-006)130
Unknown
不适用
一项研究者发起的抗病毒治疗中断（ATI）后治疗用艾滋病核酸注射液（ICVAX）对 HIV-1 感染者的安全性和有效性研究ChiCTR2600116412深圳医克生物医药有限公司
尚未招募
不适用
Evaluation of HIV-Positive individuals’ Weariness And how it affects their quality of lifeCTRI/2024/04/065791Maulana azad medical college40